SonoScape released its 2026 semi-annual report, showing operating revenue of 1.053 billion yuan, up 9.24% year on year, but net profit attributable to shareholders of the listed company was 13.7763 million yuan, down 70.71% year on year. Net profit after deducting non-recurring gains and losses fell to 2.4852 million yuan, a year-on-year decline of 93.77%. The company said a sharp increase in foreign exchange losses and continued investment in new product lines were the two main factors dragging down profit. Financial expenses swung from negative 35.0741 million yuan in the same period last year to 25.1523 million yuan, a year-on-year surge of 171.71%. After excluding the impact of foreign exchange gains and losses and share-based payments, actual operating profit for the first half was about 70.47 million yuan, up about 114% year on year. By region, international business revenue rose 14.6% year on year and now accounts for more than half of the total, while domestic business revenue rose 3.7% year on year, though domestic ultrasound and endoscopy product revenue declined due to reduced tendering activity.
SonoScape Medical CorpNet profit down 70.71% year on year due to FX losses and new product investment.
